TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the release of its sixth annual 2025 Industry Trends Survey. This year’s report explores how public safety professionals use and apply powerful digital investigative solutions to uncover digital evidence in criminal investigations. For the first time, the survey reveals a widespread appetite for ...

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the release of its sixth annual 2025 Industry Trends Survey. This year's report explores how public safety professionals use and apply powerful digital investigative solutions to uncover digital evidence in criminal investigations. For the first time, the survey reveals a widespread appetite for ...

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the general availability of Generative Artificial Intelligence (GenAI) capabilities within Guardian, the Company’s SaaS-based evidence management solution. By incorporating GenAI into Guardian, public safety agencies benefit from AI-driven productivity. Users can now form a more complete picture ...

Group 1 - Cellebrite DI Ltd. (NASDAQ: CLBT) offers digital tools to governmental agencies such as the FBI and CIA, positioning itself uniquely in the SaaS market [1] - The company operates in a sector with numerous competitors providing digital solutions and software [1] Group 2 - The analyst emphasizes a medium to long-term investment horizon for selected companies, indicating a strategic approach to investment rather than a momentum-based strategy [1]

My primary area of concentration will be on identifying companies of exceptional caliber, with a proven ability to reinvest capital for impressive returns. Targeting those with a market capitalization of less than $10 billion, affords ample opportunities for growth. The ideal scenario is for these companies to demonstrate a long-term capability of capital compounding, with a high enough compound annual growth rate to potentially deliver tenfold returns or even greater.My approach is to maintain a long-term ...

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced it will report its fourth-quarter and fiscal year 2024 financial results before market open on Thursday, February 13, 2025. Later that same morning, Cellebrite will host a live conference call and webcast to review the Company's financial results for the fourth quarter of 2024 and discuss its 20 ...

Group 1 - Cellebrite will participate in the Needham & Company 27th Annual Growth Conference on January 14, 2025, at 8:45 a.m. ET in a fireside chat format [1] - The company is recognized as a global leader in Digital Investigative solutions for both public and private sectors [2] - Cellebrite's mission focuses on enabling customers to protect lives, accelerate justice, and preserve privacy through streamlined digital investigations [2] Group 2 - The company’s Digital Investigation platform is designed to transform how organizations collect, review, analyze, and manage data in legally sanctioned investigations [2] - Cellebrite is trusted by thousands of leading agencies and companies worldwide, highlighting its significant market presence [2] - For further information, investors can visit Cellebrite's official website or follow the company on Twitter [2]

Core Points - Cellebrite has confirmed Thomas E. Hogan as interim CEO as part of a planned leadership transition for 2025 [2] - Adam H. Clammer has taken on the role of board chairman, ensuring the separation of duties between the CEO and board chair [3] - Michael D. Capellas has been appointed to the Board of Directors as a Class II director and will serve as the lead independent director [4] Company Leadership Changes - Thomas E. Hogan will revert to his position as chairman once a new CEO is appointed [2] - Adam H. Clammer, previously the lead independent director, now serves as board chairman [3] - Michael D. Capellas brings extensive leadership experience from various technology companies and is expected to enhance the board's capabilities [5] Company Mission and Vision - Cellebrite aims to protect and save lives, accelerate justice, and preserve privacy globally through its Digital Investigative solutions [9] - The company is committed to combating issues such as child exploitation and trafficking, aligning with its mission to enhance community safety [5]

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Cellebrite (Nasdaq: CLBT), a global leader in premier digital investigative solutions for the public and private sectors, and Relativity, a global legal technology company, announced today the general availability of the integration of Cellebrite’s mobile collection solutions, Endpoint Inspector and Endpoint Mobile Now, into the RelativityOne platform. The need for mobile collection in legal processes continues to grow and this ne ...

Core Insights - Investors in the Technology Services sector should consider Nu Holdings Ltd. (NU) and Cellebrite DI Ltd. (CLBT) for potential value opportunities [1] Valuation Metrics - Nu Holdings Ltd. has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Cellebrite DI Ltd. has a Zacks Rank of 3 (Hold) [3] - NU has a forward P/E ratio of 37.15, compared to CLBT's forward P/E of 44.66, suggesting NU is more attractively valued [5] - The PEG ratio for NU is 0.69, indicating better growth prospects relative to its valuation, while CLBT's PEG ratio is 1.95 [5] - NU's P/B ratio is 10.48, while CLBT's P/B ratio is 12.85, further supporting NU's superior valuation metrics [6] Investment Conclusion - NU has demonstrated stronger estimate revision activity and more favorable valuation metrics than CLBT, making it a more appealing option for value investors [7]